The FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based on a filing that drew heavily on post-marketing and real-world data.
Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...